Phase Ib Study With the Combination of LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients - The CoLBAt Trial

This Phase Ib trial studies the side effects and best dose of LB-100 when given with atezolizumab for the treatment of patients with metastatic microsatellite stable colorectal cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of the tumor to grow and spread. LB-100 has been shown to make anticancer drugs work better at killing cancer. LB-100 blocks a protein on the surface of cells called PP2A. Blocking this protein increases the stress signals for the tumor cells that express PP2A. Giving atezolizumab in combination with LB-100 may work better to treat metastatic colorectal cancer patients as the cancer cells that experience increased stress signals are more susceptible for the immunotherapy.

开始日期2023-12-01

申办/合作机构

Netherlands Cancer Insitute

NCT06065462 / Recruiting临床1/2期IIT

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma

开始日期2023-11-10

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+2]

NCT05809830 / Recruiting临床1/2期

Phase I/II Randomized Trial of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

A Phase I dose-finding stage for the LB-100 plus doxorubicin combination is planned for an initial set of 9-18 patients (21-day cycles). After that, in the Phase II part, patients will be randomized (ratio 1:1) to either the experimental arm (LB-100 plus doxorubicin combination) or the control arm (doxorubicin alone) to, comparatively, evaluate the efficacy of the LB-100 plus doxorubicin combination vs. doxorubicin alone

开始日期2023-05-29

申办/合作机构

Grupo Español de Investigación en Sarcomas

100 项与 LB-100 相关的临床结果

登录后查看更多信息

100 项与 LB-100 相关的转化医学

登录后查看更多信息

100 项与 LB-100 相关的专利（医药）

登录后查看更多信息

项与 LB-100 相关的文献（医药）

2023-02-01·Surgery Today

Functional evaluations comparing Billroth I with a large remnant stomach and Roux en Y with a small remnant stomach following laparoscopic distal gastrectomy for gastric cancer: An investigation including laparoscopic total gastrectomy

Article

作者: Mukai, Masaya ; Seki, Takatoshi ; Makuuchi, Hiroyasu ; Izumi, Hideki ; Ninomiya, Yamato ; Nakamura, Kenji ; Nomura, Eiji ; Yamamoto, Soichiro ; Nabeshima, Kazuhito

Abstract:

Purpose:

This study compared the pros and cons of two post-distal gastrectomy (DG) reconstruction methods by comparing the patient quality of life and functional dynamics at one year postoperatively.

Methods:

We compared functional outcomes between Billroth I following laparoscopic 1/2 DG (L-B1; n = 27) and Roux en Y following laparoscopic 4/5 DG (L-RY; n = 24), including laparoscopic total gastrectomy (L-TG; n = 25), at one year postoperatively. Clinical investigations were performed in each patient, and functional evaluations by the acetaminophen (AAP) absorption test and plasma gastrointestinal hormone measurements were performed in consenting patients in each group (L-B1: n = 10, L-RY: n = 10, L-TG: n = 5).

Results:

Postoperative/preoperative body weight ratios were significantly higher in the L-B1 and L-RY groups, in descending order than the L-TG group, although the meal intake ratio was not significantly different between the L-B1 and L-RY groups. The incidence of remnant gastritis was significantly higher in the B1 than in the RY group. AAP levels, glucose and glucagon-like peptide 1 were significantly lower in the L-B1 than in the L-RY group. Active ghrelin levels (AGL) were similar between the L-B1 and L-RY groups.

Conclusions:

L-B1 maintains gradual intestinal absorption and physiological meal passage and prevents postoperative weight loss. L-RY results in maintenance of the postoperative meal intake via high AGL, equivalent to that in the L-B1 group.

2023-01-03·Journal of animal science

Microencapsulation protected Lactobacillus viability and its activity in modulating the intestinal microbiota in newly weaned piglets.

Article

作者: Yin, Fugui ; Lo Verso, Luca ; Wang, Qi ; Yu, Hai ; Lepp, Dion ; Yang, Chengbo ; Nie, Shaoping ; Gong, Joshua ; Yang, Chongwu ; Wang, Xiaoyin ; Lessard, Martin ; Li, Linyan ; Mondor, Martin

Lactobacilli are sensitive to heat, which limits their application as probiotics in livestock production. Lactobacillus rhamnosus LB1 was previously shown to reduce enterotoxigenic Escherichia coli (ETEC) and Salmonella infections in pigs. To investigate its potential in the application, the bacterium was microencapsulated and examined for its survival from feed pelleting and long-term storage as well as its function in modulating pig intestinal microbiota. The in vitro studies showed that freshly microencapsulated Lactobacillus rhamnosus LB1 had viable counts of 9.03 ± 0.049 log10 colony-forming units/g, of which only 0.06 and 0.87 Log of viable counts were reduced after storage at 4 and 22 °C for 427 d. The viable counts of encapsulated Lactobacillus rhamnosus LB1 were 1.06 and 1.54 Log higher in the pelleted and mash feed, respectively, than the non-encapsulated form stored at 22 °C for 30 d. In the in vivo studies, 80 piglets (weaned at 21 d of age) were allocated to five dietary treatments for a 10-d growth trial. The dietary treatments were the basal diet (CTL) and basal diet combined with either non-encapsulated LB1 (NEP), encapsulated LB1 (EP), bovine colostrum (BC), or a combination of encapsulated LB1 and bovine colostrum (EP-BC). The results demonstrated that weaning depressed feed intake and reduced growth rates in pigs of all the treatments during 21 to 25 d of age; however, the body weight gain was improved during 25 to 31 d of age in all groups with the numerically highest increase in the EP-BC-fed pigs during 21 to 31 d of age. Dietary treatments with EP, particularly in combination with BC, modulated pig intestinal microbiota, including an increase in Lactobacillus relative abundance. These results suggest that microencapsulation can protect Lactobacillus rhamnosus LB1 against cell damage from a high temperature during processing and storage and there are possible complementary effects between EP and BC.

2022-12-01·Cellular Oncology

Inhibition of PP2A by LB100 sensitizes bladder cancer cells to chemotherapy by inducing p21 degradation

Article

作者: Li, Xinyu ; Gao, Song ; Ye, Mingliang ; Zhan, Xi ; Shan, Liping ; Tao, Xinyi ; Zhang, Mo ; Wang, Yan ; Liu, Yang ; Yin, Yalei ; Jiang, Zhonghao

PURPOSE:

Bladder carcinoma (BLCA) is the most common urinary tract malignancy and exhibits a poor response to chemotherapy. Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase involved in a wide variety of regulatory cellular processes, including apoptosis and the DNA-damage response (DDR). LB100, a small molecule inhibitor of PP2A, has been shown to act as a chemo-sensitizer in multiple types of cancer. However, the anti-tumor effect and mode of action of LB100 in BLCA have yet to be identified.

METHODS:

In vitro and in vivo experiments were performed to assess the anti-tumor effect of LB100 alone or in combination with gemcitabine. Mass spectrometry (MS)-based phosphoproteomics analysis was used to identify the downstream substrates of PP2A and to explore the mechanism underlying LB100-induced DNA damage and apoptosis. In addition, we established a chemo-resistant BLCA cell line (RT-112-R) by prolonged drug exposure and determined the effect of LB100 in enhancing genotoxicity in BLCA cell lines and xenograft mouse models.

RESULTS:

We found that LB100 is sufficient to induce an anti-tumor response in BLCA cells by inducing DNA damage and apoptosis both in vitro and in vivo. Furthermore, we found that PP2A potentially dephosphorylates p-p21-ser130 to stabilize p21. Inhibition of PP2A by LB100 increased the level of p-p21-ser130, subsequently leading to a reduction in p21 level in a dose-dependent manner. In addition, we found that treatment of LB100 abrogated the G1/S cell cycle checkpoint, resulting in increased phosphorylation of γH2AX in BLCA cells. Moreover, LB100 enhanced genotoxicity in chemo-resistant BLCA cells by inducing DNA damage and apoptosis in vitro and in vivo.

CONCLUSION:

Our findings indicate that PP2A may serve as a potential therapeutic target in BLCA through regulating p21 stability.

项与 LB-100 相关的新闻（医药）

2024-04-01

·奇点网

谁说过度激活杀不死癌细胞呢？

*仅供医学专业人士阅读参考听到“XX信号通路促癌”，大多数读者的第一反应是不是像奇点糕一样，想着“抑制，赶紧抑制”？理所应当，无可厚非的思考回路，但也不妨反向思考一下：如果让某些促癌信号通路过度激活，会不会两极反转一下，带来抑癌作用呢？近日在Cancer Discovery期刊上，荷兰癌症研究所的研究团队发表了一篇最新研究，就尝试将这种“过度激活”策略用于结直肠癌治疗，发现抑制蛋白质磷酸酶-2A（PP2A）可过度激活多条促癌信号通路，并激活癌细胞的应激反应通路，再进一步抑制WEE1可实现“合成致死”，使癌细胞DNA复制遇阻，且过早发生有丝分裂而死亡[1]。论文首页截图看到肠癌、过度激活、合成致死这几个关键词，奇点糕第一时间想到的其实是去年MIT/哈佛团队发表的一项研究，那项研究发现过度激活部分肠癌中的WNT信号通路，可带来显著的抑癌作用[2]，荷兰研究者们此前就将这种策略命名为“看似自相矛盾的干预策略”[3]：过度激活特定信号通路，就会让癌细胞在应激反应中对其过于依赖，最终暴露出致命弱点。而此次研究的主角PP2A早在十几年前就被证明是一种抑癌因子，而且能够抑制多条关键的促癌信号通路，用它来验证“过度激活”是否可行确实不错。借助此前开发的小分子PP2A抑制剂（LB-100）[4]，研究者们首先证实，抑制PP2A确实可过度激活结直肠癌细胞内的MAPK、WNT/β-catenin等关键信号通路，它们也决定着PP2A抑制剂的杀伤力。但只做到这一步显然还不够，不然PP2A抑制剂早就可以单独出道了，所以接下来，研究者们尝试去寻找“合成致死”的突破口，也就是抑制PP2A后癌细胞过度激活特定信号通路暴露出的破绽，为此研究者们使用的方法是药物筛选，从靶向应激反应（包括DNA损伤应激、氧化应激、代谢应激等）的各种药物中，将靶向CHK1和WEE1的小分子抑制剂挑了出来。结合基于CRISPR技术的筛选，研究者们确定同时抑制PP2A和WEE1能够实现“合成致死”，且鉴于靶向CHK1的药物开发很不顺利，后续研究的重点就放到了抑制PP2A和WEE1的方向；体外细胞实验证实，在研的WEE1抑制剂adavosertib与LB-100确实可协同增效，更好地抑制多个肠癌细胞系，效果明显优于单药使用或两种药物分别联合化疗的效果。adavosertib与LB-100存在协同增效作用WEE1抑制剂的抑癌机制主要是使癌细胞过早进入细胞周期，尚未完成修复的DNA损伤就可能会在细胞分裂过程中，引发有丝分裂灾变（mitotic catastrophe）和细胞凋亡，而抑制PP2A的起效也有一部分要归功于干预细胞分裂。本次研究也证实，adavosertib与LB-100联合治疗，确实可使大多数进入有丝分裂过程的肠癌细胞发生有丝分裂灾变。进一步上溯其原因时，研究者们发现adavosertib与LB-100的联合使用，会使癌细胞DNA复制叉的速度减慢，导致DNA复制过程陷入停滞，而还没完成DNA复制的癌细胞就要赶着去完成有丝分裂，这基本就是“赶着投胎”了，死得一点都不冤。adavosertib与LB-100联合治疗，加速癌细胞“自取灭亡”的机制最后，研究者们在小鼠身上利用肿瘤患者来源类器官，证实了adavosertib与LB-100联合治疗的协同增效机制，并确认该方案不会导致显著的系统性毒性；更妙的是，癌细胞如果要对这套联合治疗方案产生获得性耐药，就要被迫下调关键促癌信号通路（即MAPK、WNT/β-catenin）的激活水平，这同样会起到抑癌作用，真是巧妙的“两头堵”啊。参考文献：[1]Dias M H, Friskes A, Wang S, et al. Paradoxical activation of oncogenic signaling as a cancer treatment strategy [J]. Cancer Discovery, 2024.[2]Chang L, Jung N Y, Atari A, et al. Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities[J]. Nature Genetics, 2023, 55(10): 1709-1720.[3]Dias M H, Bernards R. Playing cancer at its own game: activating mitogenic signaling as a paradoxical intervention[J]. Molecular Oncology, 2021, 15(8): 1975-1985.[4]Chung V, Mansfield A S, Braiteh F, et al. Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial[J]. Clinical Cancer Research, 2017, 23(13): 3277-3284.本文作者丨谭硕

基因疗法临床结果

2024-03-27

·GlobeNewswire-Health Care

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” The finding opens a potentially new treatment strategy in addition to LIXTE’s current three clinical trials. As will be published in the July 2024 issue and posted online today, LB-100 was shown to trigger hyper-activation of the signals that are responsible for the deregulated proliferation of cancer cells, which is the opposite of most of the current generation of cancer therapies. The deliberate hyper-activation of cancer signals becomes lethal when combined with an inhibitor of the WEE1 kinase. This well-tolerated combination proved to be highly effective in killing colon cancer cells in animal models of cancer and in cell culture. Resistance to therapy is the leading cause of death due to cancer. Resistance to LB-100 therapy, however, has been shown to be associated with cancer cells becoming less malignant. Specifically, colon cancer cells that developed resistance to LB-100 had lost many of the features that make the cells cancerous in the first place and were unable to form tumors in experimental animal models. This “tumor suppressive drug resistance” stems from the unique features of LB-100. Although cancer-causing signals force cancer cells to become more cancerous, the hyper-activation of these signals by LB-100 forces cancer cells to suppress these signals and thus become less cancerous. The team of scientists reporting these findings was headed by Professor René Bernards at the Netherlands Cancer Institute and Oncode Institute, Amsterdam. Professor Bernards is a a leader in the field of molecular carcinogenesis and is a member of the Board of Directors of LIXTE. Bas van der Baan, Chief Executive Officer of LIXTE, said, “The effect of LB-100 on cancer cells is unique in that the only way for cancer cells to escape death is to evolve toward a less cancerous behavior. We look forward to testing this concept clinically, which is distinct from the well-characterized enhancement of checkpoint immunotherapy and chemotherapy by LB-100 currently being tested in three clinical trials.” About LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE's new approach has no known competitors and is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are in progress. Forward-Looking Statement Disclaimer This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors. Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For more information about LIXTE, Contact: info@lixte.com General Phone: (631) 830-7092; Investor Phone: (888) 289-5533 or PondelWilkinson Inc. Investor Relations pwinvestor@pondel.comRoger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962

免疫疗法临床研究

2024-03-21

·GlobeNewswire-Health Care

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100. “Clinical trials are underway at leading cancer centers in the United States and Spain using LB-100 in combination with chemotherapy and immunotherapy that we are hopeful will provide new and effective treatment options for patients with lung, ovarian and sarcoma cancers,” said Bas van der Baan, LIXTE’s President and Chief Executive Officer. Clinical trials are taking place at the University of Texas MD Anderson Cancer (ovarian clear cell carcinoma); City of Hope Cancer Center and the Sarah Cannon Research Institute (small cell lung cancer); and the Spanish Sarcoma Group (advanced soft tissue sarcoma). Click here for a brief video overview by LIXTE’s Chief Executive Officer. LIXTE recently announced the following significant developments: The dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LB-100 to GSK’s dostarlimab-gxly will enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC). The clinical trial was initiated by, and is being conducted at, the University of Texas MD Anderson Cancer Center. LIXTE is providing LB-100, and GSK is providing dostarlimab-gxly and financial support.The signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke and the National Cancer Institute, each an Institute of the National Institutes of Health (NIH). LIXTE has licensed NIH’s intellectual property rights under a Cooperative Research and Development Agreement that, focused on LB-100 promoting anti-cancer activity alone and in combination with immune checkpoint inhibitors.On February 28, 2024, René Bernards, PhD, a leader in the field of molecular carcinogenesis and Senior Staff Scientist at the Netherlands Cancer Institute, presented new pre-clinical data at the Joint Conference of European and American Associations for Cancer Research in Dublin, Ireland on how stress imposed onto colon cancer cells by LB-100 drives cancer cells to evolve to less cancerous behavior, underscoring a unique mechanism of action of LB-100. Dr. Bernards is a member of the Board of Directors of LIXTE. Filing of Annual Report on Form 10-K for the fiscal year ended December 31, 2023 Additional information with respect to LIXTE’s business, clinical trials and financial condition is contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which has been filed with the U.S. Securities and Exchange Commission at www.sec.gov. About LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy, PP2A inhibitors. The Company’s novel approach enhances the efficacy of both chemotherapy and immunotherapy, potentially providing new treatment options for patients. At the core of the Company’s therapy is LB-100, LIXTE’s proprietary molecule that acts as an inhibitor of the PP2A phosphatase with a favorable toxicity profile. LB-100 promotes the production of neoantigens and cytokines, boosts T-cell proliferation, and disrupts the DNA repair mechanisms of cancer cells, potentially improving treatment outcomes. The Company is conducting multiple clinical trials for solid tumors with unmet medical needs. LIXTE’s unique approach has no known competitors and is covered by a comprehensive patent portfolio. Additional information about LIXTE can be found at www.lixte.com. Forward-Looking Statement Disclaimer This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors. Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For more information about LIXTE, Contact: info@lixte.com General Phone: (631) 830-7092 Investor Phone: (888) 289-5533 or PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com Roger Pondel or Laurie Berman: (310) 279-5980 # # #

免疫疗法引进/卖出临床研究

100 项与 LB-100 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15412

研发状态

适应症	最高研发状态	国家/地区	公司
实体瘤	临床2期	西班牙更多	Lixte Biotechnology Holdings, Inc. 更多
血液肿瘤	临床2期	西班牙更多	Lixte Biotechnology Holdings, Inc. 更多
广泛期小细胞肺癌	无进展	美国更多	City of Hope National Medical Center 更多
晚期恶性实体瘤	无进展	美国更多	Lixte Biotechnology Holdings, Inc. 更多
骨髓增生异常综合征	无进展	美国更多	Lixte Biotechnology Holdings, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03027388 (CTgov)	临床2期	少突神经胶质瘤 \| 复发性胶质母细胞瘤 \| 多形性胶质母细胞瘤	7	LB-100	築淵網願顧壓餘簾繭獵(衊窪簾鑰鬱鹹鏇衊簾憲) = 觸廠膚鹹壓顧襯壓淵襯壓夢繭遞繭夢鹽膚遞膚 (願鏇窪遞築觸淵憲製網, 鑰構鹽衊糧窪夢觸願夢 ~ 醖醖壓衊顧窪選簾壓簾) 更多	-	2023-11-22